alzheimer’s

The grant will support research into a new drug that could potentially prevent the onset of Alzheimer’s disease. read more >

The finding comes after UAMS built the first known full-length structure of the Alzheimer’s gene protein in 2017. read more >

The goal of the research is to test and potentially treat a newly discovered element of energy usage in the brains of Alzheimer’s patients read more >

Japanese drugmaker Eisai received conditional approval from the FDA in January based on early results suggesting Leqembi worked by clearing a sticky brain plaque linked to the disease. read more >

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release. read more >

The criticism comes as the FDA is expected to decide whether to approve another new Alzheimer's drug in January. read more >

The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer's -- can delay disease progression. read more >

The move comes as legislation to authorize Medicare to negotiate prescription drug prices remains stuck in the Senate. read more >

The directive comes after drugmaker Biogen slashed the price of the medication. read more >